Medtronic (MDT) Offering Possible 22.55% Return Over the Next 28 Calendar Days

This article was originally published on this site

Medtronic’s most recent trend suggests a bullish bias. One trading opportunity on Medtronic is a Bull Put Spread using a strike $82.50 short put and a strike $77.50 long put offers a potential 22.55% return on risk over the next 28 calendar days. Maximum profit would be generated if the Bull Put Spread were to expire worthless, which would occur if the stock were above $82.50 by expiration. The full premium credit of $0.92 would be kept by the premium seller. The risk of $4.08 would be incurred if the stock dropped below the $77.50 long put strike price.

The 5-day moving average is moving up which suggests that the short-term momentum for Medtronic is bullish and the probability of a rise in share price is higher if the stock starts trending.

The 20-day moving average is moving up which suggests that the medium-term momentum for Medtronic is bullish.

The RSI indicator is at 64.39 level which suggests that the stock is neither overbought nor oversold at this time.

To learn how to execute such a strategy while accounting for risk and reward in the context of smart portfolio management, and see how to trade live with a successful professional trader, view more here


LATEST NEWS for Medtronic

Medtronic Begins U.S. Study of Drug-Eluting Stents to Evaluate Treatment of Bifurcation Lesions in Patients with Coronary Artery Disease
Wed, 16 May 2018 14:02:01 +0000
Medtronic Received IDE Approval from FDA to Generate Clinical Evidence with Resolute Onyx DES to Support Future Application for Expanded Indication in U.S. DUBLIN – May 16, 2018 – Medtronic plc (MDT) today announced the initiation of a clinical study in the U.S. to assess the safety and efficacy of drug-eluting stents (DES) for the treatment of bifurcation lesions, which account for approximately 20 percent of all percutaneous coronary interventions (PCI).1 The Bifurcation Cohort, part of the RESOLUTE ONYX Post-Approval Study, will include patients with coronary artery disease (CAD) receiving the Resolute Onyx(TM) DES in sizes ranging from 2.0 mm – 5.0 mm in diameter.

Detailed Research: Economic Perspectives on Medtronic, NVIDIA, NutriSystem, AmTrust Financial Services, Kratos Defense & Security Solutions, and Envision Healthcare — What Drives Growth in Today’s Competitive Landscape
Wed, 16 May 2018 12:25:00 +0000
NEW YORK, May 16, 2018– In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Medtronic …

Mazor Robotics Starts Its “Transition” Year Strong
Tue, 15 May 2018 20:57:00 +0000
Business is booming for the robotic surgery upstart.

Mazor Robotics (MZOR) Q1 2018 Earnings Conference Call Transcript
Tue, 15 May 2018 14:44:54 +0000
MZOR earnings call for the period ending March 31, 2018.

New Analysis Shows Medtronic Cardiac Resynchronization Therapy Feature Associated with Improved Patient Survival
Tue, 15 May 2018 14:02:02 +0000
Real-World Data on AdaptivCRT(TM) Algorithm Presented at Heart Rhythm 2018 DUBLIN – May 15, 2018 – Medtronic plc (NYSE: MDT) announced study results showing its exclusive AdaptivCRT(TM) algorithm is associated …

Be Sociable, Share!

Related Posts